Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
Open Access
- 14 September 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1226086
Abstract
Objective: To investigate and analyze the post-marketing adverse event (AE) data of multiple sclerosis (MS) therapeutic drug dalfampridine using the US Food and Drug Administration Adverse Event Reporting System (FAERS) for its clinical safety application.Methods: Use OpenVigil2.1 platform to obtain AE data of dalfampridine from FAERS from February 2010 to September 2022. Match “adverse drug reaction” with preferred term (PT) and system organ class (SOC) according to the Medical Dictionary for Regulatory Activities (MedDRA), then merge the same PT and delete non-AE PT. Positive signals were identified by the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) methods. When AE signals met the criteria of those three methods, they were identified as positive signals.Results: A total of 44,092 dalfampridine-related AE reports were obtained, and 335 AE signals were identified, including 11,889 AE reports. AEs were more common in females and in the 45–65 age group, which is consistent with the epidemiological characteristics of MS. The 335 AE signals involved 21 SOCs, including investigations, infections and infestations, eye disorders, etc. Among the top 20 PTs in signal strength, 10 were associated with abnormal lymphocyte percentage and count, and 5 were associated with abnormal urine tests, some of which were not described in the instruction, such as spinal cord injury cauda equina, haemoglobin urine present, urinary sediment abnormal and so on. The most frequently reported AE signals were urinary tract infection, dizziness, condition aggravated. In addition, 23 AE signals with death outcomes were identified, with an incidence of less than 0.1%.Conclusion: Data mining of FAERS was conducted to analyze the AEs of dalfampridine, and new AE signals were found. This study provides a reference for the safe use of dalfampridine in the treatment of MS.Keywords
Funding Information
- Natural Science Foundation of Chongqing Municipality
This publication has 28 references indexed in Scilit:
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology, 2014
- Liver and kidney damage induced by 4-aminopyridine in a repeated dose (28 days) oral toxicity study in rats: Gene expression profile of hybrid cell deathToxicology Letters, 2014
- Dalfampridine: A Medication to Improve Walking in Patients with Multiple SclerosisAnnals of Pharmacotherapy, 2012
- Impact of Walking Impairment in Multiple SclerosisThe Patient - Patient-Centered Outcomes Research, 2011
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAnnals of Neurology, 2010
- Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal ImpairmentThe Journal of Clinical Pharmacology, 2010
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialThe Lancet, 2009
- Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuableMultiple Sclerosis Journal, 2008
- Vitamin B12, demyelination, remyelination and repair in multiple sclerosisJournal of the Neurological Sciences, 2005
- Motor conduction velocity in the human spinal cord: slowed conduction in multiple sclerosis and radiation myelopathy.Journal of Neurology, Neurosurgery & Psychiatry, 1985